Target Validation Information
TTD ID	T92138
Target Name	Phosphodiesterase (PDE)
Type of Target	Clinical trial
Drug Potency against Target	NM-702	Drug Info	IC50 = 0.179~0.26 nM	[1]
Action against Disease Model	NM-702	Drug Info	We investigated the effects of NT-702, a selective phosphodiesterase (PDE) 3 inhibitor, on arterioles isolated from rabbit l uMbar spinal cords. NT-702 caused a dose-dependent dilation of the isolated spinal arterioles. The disruption of endotheli uM produced a significant reduction of higher concentrations (10(-7) and 10(-6) M), but not lower concentrations (less than 10(-8) M), of NT-702-induced vasodilation. The NT-702-induced vasodilation of the arterioles with endotheli uM was not affected by pretreatment with an inhibitor of nitric oxide, cyclooxygenase, or cytochrome P-450 monooxygenase. In contrast, catalase reduced significantly the higher concentrations of NT-702-induced vasodilation only. Tetraethylammoni uM (TEA) completely reduced the lower concentrations of NT-702-induced vasodilation, but decreased only partially the higher concentrations of NT-702-induced vasodilation of the arterioles with endotheli uM. Hydrogen peroxide dilated significantly theisolated arterioles with endotheli uM, the response of which was reduced significantly by TEA. KT5720 (a selective protein kinase inhibitor) significantly decreased both the lower and higher concentrations of NT-702-induced vasodilation of the arterioles with endotheli uM.	[2]
References
REF 1	NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb p... Life Sci. 2007 Sep 1;81(12):970-8.
REF 2	NT-702, a selective phosphodiesterase 3 inhibitor, dilates rabbit spinal arterioles via endothelium-dependent and endothelium-independent mechanisms. J Physiol Sci. 2008 Aug;58(4):229-37.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.